Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
FDA-approved dose: 1.75 mg (1750 mcg) at least 45 minutes before anticipated activity.
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
On-Demand Protocol
Week | Daily Dose (mcg each) | Units (per injection) (mL) |
Standard (FDA-approved) | 1750 mcg (1.75 mg) | 53 units (0.53 mL) |
Lower Starting Dose | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
Conservative Start | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
Frequency: Inject subcutaneously at least 45 minutes before anticipated sexual activity.
Maximum: One injection per 24 hours; no more than 8 injections per month. For doses ≤15 units (≤0.15 mL), consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Alternative Daily Protocol (Exploratory)
Some research protocols have explored once-daily administration for metabolic endpoints. The following is a conservative titration schedule if daily use is being studied:
Week | Daily Dose (mcg) | Units (per injection) (mL) |
Weeks 1–8 | 500 mcg | 15 units (0.15 mL) |
Weeks 9–12 | 1000 mcg | 30 units (0.30 mL) |
Weeks 13–16 | 1500 mcg | 45 units (0.45 mL) |
Note: Daily protocols are not FDA-approved and require appropriate clinical oversight.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on on-demand use (up to 8 doses/month) or extended daily protocols.
On-demand (8 doses/month at 1.75 mg): 2 vials per month
16-week daily protocol: ~10 vials
On-demand (8/month): 8 syringes per month
16-week daily: 112 syringes
Bacteriostatic Water: Use ~3.0 mL per vial for reconstitution.
On-demand (2 vials): 6 mL
16-week daily (10 vials): 30 mL
Alcohol Swabs: One for the vial stopper + one for the injection site each use.
On-demand (8/month): 16 swabs per month
16-week daily: 224 swabs
Protocol Overview
Concise summary of the on-demand regimen.
Goal: Support sexual desire and arousal through central melanocortin receptor activation.
Schedule: On-demand subcutaneous injection ≥45 minutes before anticipated activity.
Dose: 1.75 mg (1750 mcg) per the FDA-approved regimen.
Limits: Maximum once per 24 hours; no more than 8 doses per month.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Dosing Protocol
Suggested on-demand approach.
Standard Dose: 1.75 mg (53 units) subcutaneously.
Timing: At least 45 minutes before anticipated sexual activity.
Frequency: No more than once every 24 hours.
Monthly Limit: Maximum 8 injections per month.
Route: Subcutaneous (abdomen or thigh); rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days; avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
PT-141 may cause transient blood pressure elevation; avoid use in uncontrolled hypertension.
Nausea is the most common side effect; it is typically mild and transient.
How This Works
Bremelanotide (PT-141) is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH), acting as a non-selective melanocortin receptor agonist with predominant activity at MC3R and MC4R. In the central nervous system, MC4R activation leads to enhanced dopamine release in key brain reward and arousal regions—including the nucleus accumbens and medial preoptic area—which increases sexual motivation and desire. Unlike PDE5 inhibitors (e.g., sildenafil), PT-141 does not directly affect the nitric oxide pathway; in males, its pro-erectile effect is secondary to central mechanisms stimulating nitric oxide production in penile tissue. Peripheral MC1R agonism accounts for side effects such as transient blood pressure elevation and skin hyperpigmentation.
Potential Benefits & Side Effects
Observations from clinical literature.
Benefits: Clinical trials in premenopausal women with HSDD showed PT-141 significantly improves sexual desire scores (FSFI-Desire) and reduces distress (FSDS-DAO) versus placebo.
Early studies in men demonstrated improved erectile responses with intranasal PT-141.
Common Side Effects: Nausea (~40%), flushing (~20%), headache (~11%); these are typically mild and transient.
Other Effects: Transient blood pressure elevation, skin hyperpigmentation with repeated use.
Subcutaneous administration provides ~100% bioavailability and is better tolerated than intranasal delivery.
Lifestyle Factors
Complementary strategies for best outcomes.
Maintain open communication with partners about expectations and timing.
Address underlying contributors to low desire (stress, relationship factors, hormonal status).
Limit alcohol consumption, which may blunt response or worsen nausea.
Ensure adequate sleep and stress management to support overall sexual health.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs) to avoid lipohypertrophy.
Discard needles and syringes after single use.